Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by moneycollectoron Apr 06, 2024 3:29am
101 Views
Post# 35974490

RE:RE:Milestone payments

RE:RE:Milestone payments
Two comments on this: I don't know how many times Sirona's management has said that this was the last PP... I also don't know how many statements HV has made that have turned out to be complete nonsense. The now complete inexistence of any residual credibility in the two cardboard figures in Vancouver is reflected in the share price. 
And if the actual case were to occur that the rights to 1067 were to go back to Sirona, then it's all over anyway. Because that would mean that Allergan doesn't want to do anything with the molecule or that the whole thing isn't as great as we are constantly being led to believe. And Sirona can no longer do anything with it on its own. To do so, the company needs a lot of money. But nobody gives anything to this incompetent management anymore, as the PP just showed with the ridiculous $130k
 
<< Previous
Bullboard Posts
Next >>